Related references
Note: Only part of the references are listed.Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes
Peter Valent et al.
ALLERGY (2023)
Updates on eosinophilic disorders
Alexandar Tzankov et al.
VIRCHOWS ARCHIV (2023)
The international consensus classification of mastocytosis and related entities
Roos J. Leguit et al.
VIRCHOWS ARCHIV (2023)
Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry
Vanessa E. Kennedy et al.
BLOOD ADVANCES (2023)
Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT
Juan-Carlos Hernandez-Boluda et al.
BONE MARROW TRANSPLANTATION (2022)
Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literature
Nana P. Matsumoto et al.
MODERN PATHOLOGY (2022)
t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity
Sarah B. Mueller et al.
BLOOD ADVANCES (2022)
World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management
William Shomali et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis
Ana Henriques et al.
BLOOD (2022)
Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022
Michel Arock et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis
Roberta Zanotti et al.
LEUKEMIA (2022)
PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature
Henry G. Kaplan et al.
ONCOLOGIST (2022)
Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review
Gema Requena et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)
The Neutrophil/Lymphocyte Ratio is an Independent Predictor of All-Cause Mortality in Patients with Idiopathic Hypereosinophilic Syndrome
Junshuai Xue et al.
JOURNAL OF INFLAMMATION RESEARCH (2022)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A. Arber et al.
BLOOD (2022)
Available and emerging therapies for bona fide advanced sys temic mastocytosis and pri mary eosinophilic neoplasms
Jason Gotlib
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2022)
Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis
Johannes Luebke et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
Andreas Reiter et al.
LEUKEMIA (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury et al.
LEUKEMIA (2022)
Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium
Polina Pyatilova et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)
Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis
Jason Gotlib et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)
Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)
Daniel J. DeAngelo et al.
BLOOD (2022)
Lymphocytic variant of hypereosinophilic syndrome: A report of seven cases from a single institution
Zhihong Hu et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2021)
Partial Response to Sorafenib in a Child With a Myeloid/Lymphoid Neoplasm, Eosinophilia, and a ZMYM2-FLT3 Fusion
Monica C. Munthe-Kaas et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2021)
Reactive Eosinophil Proliferations in Tissue and the Lymphocytic Variant of Hypereosinophilic Syndrome 2019 Society for Hematopathology/European Association for Haematopathology Workshop Report
Rebecca L. King et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2021)
Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2
Olga Pozdnyakova et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2021)
Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders Report of the 2019 Society for Hematopathology/European Association for Haematopathology Workshop
Katalin Kelemen et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2021)
A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN FGFR1)
Jason Gotlib et al.
BLOOD (2021)
Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study
Javier Munoz-Gonzalez et al.
LANCET HAEMATOLOGY (2021)
Hypereosinophilic syndromes-An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment
Grzegorz Helbig et al.
BLOOD REVIEWS (2021)
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
Robin L. Jones et al.
EUROPEAN JOURNAL OF CANCER (2021)
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
Jason Gotlib et al.
NATURE MEDICINE (2021)
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
Daniel J. DeAngelo et al.
NATURE MEDICINE (2021)
Myeloid/lymphoid neoplasms with FLT3 rearrangement
Guilin Tang et al.
MODERN PATHOLOGY (2021)
ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML
Barbara Spitzer et al.
BLOOD ADVANCES (2021)
Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity
Peter Valent et al.
SEMINARS IN IMMUNOPATHOLOGY (2021)
Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance
Justin Anthony Chen et al.
BLOOD ADVANCES (2021)
Myeloid/lymphoid neoplasm with CEP110-FGFR1 fusion: An analysis of 16 cases show common features and poor prognosis
Meiyu Chen et al.
HEMATOLOGY (2021)
Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis
Hanneke C. Kluin-Nelemans et al.
THERANOSTICS (2021)
Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing
Alexander K. Chao et al.
LEUKEMIA (2020)
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification
Jakub Trizuljak et al.
ALLERGY (2020)
Omalizumab in the treatment of adult patients with mastocytosis: A systematic review
Fatma Jendoubi et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2020)
Systematic use of fluorescence in-situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms
Hong Fang et al.
HISTOPATHOLOGY (2020)
Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis
Jeffrey W. Craig et al.
MODERN PATHOLOGY (2020)
The Spectrum of Aggressive Mastocytosis: A Workshop Report and Literature Review
Roos Leguit et al.
PATHOBIOLOGY (2020)
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes
Juliana Schwaab et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia
Monica Kasbekar et al.
BLOOD ADVANCES (2020)
Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial
Florence Roufosse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications
Sanjeev Kumar Gupta et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement
Haipeng Shao et al.
LEUKEMIA RESEARCH (2020)
Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement
Timothy Carll et al.
BLOOD ADVANCES (2020)
A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia
Max Jan et al.
BLOOD ADVANCES (2020)
Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation
Georgia Metzgeroth et al.
BLOOD ADVANCES (2020)
A Novel t(1;9)(p36;p24.1) JAK2 Translocation and Review of the Literature
Hannah Levavi et al.
ACTA HAEMATOLOGICA (2019)
Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome
F. L. Kuang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Chronic myelomonocytic leukemia with ETV6-ABL1 rearrangement and SMC1A mutation
Melissa H. Cessna et al.
CANCER GENETICS (2019)
Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management
Animesh Pardanani
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia
Nicholas C. P. Cross et al.
LEUKEMIA (2019)
Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study
Guilin Tang et al.
MODERN PATHOLOGY (2019)
International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study
Wolfgang R. Sperr et al.
LANCET HAEMATOLOGY (2019)
Myeloid/lymphoid neoplasms with FGFR1 rearrangement
Paolo Strati et al.
LEUKEMIA & LYMPHOMA (2018)
A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow A Single Institutional Experience
Hong Fang et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2018)
Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group
Kathryn G. Roberts et al.
BLOOD (2018)
Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis
Nicole Naumann et al.
GENES CHROMOSOMES & CANCER (2018)
Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2
Constance Baer et al.
HAEMATOLOGICA (2018)
Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement
Kento Umino et al.
HEMATOLOGY (2018)
How I investigate Clonal cytogenetic abnormalities of undetermined significance
G. Tang et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2018)
Prevalence of CD30 immunostaining in neoplastic mast cells: A retrospective immunohistochemical study
Geisilene Russano de Paiva Silva et al.
MEDICINE (2018)
Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2
Constance Baer et al.
HAEMATOLOGICA (2018)
A multimodality work-up of patients with Hypereosinophilia
Zhihong Hu et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases
Sahrish Shah et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors
Wei Xie et al.
CANCER GENETICS (2018)
Impact of somatic and germline mutations on the outcome of systemic mastocytosis
Javier I. Munoz-Gonzalez et al.
BLOOD ADVANCES (2018)
Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models
Animesh Pardanani et al.
BLOOD ADVANCES (2018)
Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia
Thai Hoa Tran et al.
BLOOD ADVANCES (2018)
Two myeloid leukemia cases with rare FLT3 fusions
Haijiao Zhang et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2018)
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
Peter Valent et al.
BLOOD (2017)
A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?
E. Troadec et al.
LEUKEMIA (2017)
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome
Sa A. Wang et al.
HAEMATOLOGICA (2017)
Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis
Jason Gotlib
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2017)
Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase
Ximena Montenegro-Garreaud et al.
HUMAN PATHOLOGY (2017)
Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia
M. Jawhar et al.
LEUKEMIA (2017)
A precision therapy against cancers driven by KIT/PDGFRA mutations
Erica K. Evans et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia
Alfred Chung et al.
CANCER GENETICS (2017)
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome
Sa A. Wang et al.
HAEMATOLOGICA (2017)
Idiopathic hypereosinophilia is clonal disorder? Clonality identified by targeted sequencing
Jee-Soo Lee et al.
PLOS ONE (2017)
Philadelphia chromosome-like acute lymphoblastic leukemia
Sarah K. Tasian et al.
BLOOD (2017)
Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers
Mohamad Jawhar et al.
BLOOD (2017)
Guideline for the investigation and management of eosinophilia
Nauman M. Butt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Expression of CD2 and CD25 on Mast Cell Populations Can be Seen Outside the Setting of Systemic Mastocytosis
Sindhu Cherian et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+advanced systemic mastocytosis
M. Jawhar et al.
LEUKEMIA (2016)
Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival
Animesh Pardanani et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients
Lisa Pieri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis
Celalettin Ustun et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Characterization of leukemias with ETV6-ABL1 fusion
Marketa Zaliova et al.
HAEMATOLOGICA (2016)
Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology
Karin Hartmann et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis
Ivan Alvarez-Twose et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing
A. Pardanani et al.
LEUKEMIA (2016)
Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report
Lanshan Huang et al.
MEDICINE (2016)
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified
Sa A. Wang et al.
MODERN PATHOLOGY (2016)
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis
Jason Gotlib et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6-LYN gene fusion
N. Telford et al.
BLOOD CANCER JOURNAL (2016)
Long-term outcomes of imatinib in patients with FIP1L1/PDGFRA associated chronic eosinophilic leukemia: experience of a single center in china
Shi-Qiang Qu et al.
ONCOTARGET (2016)
Characterization of leukemias with ETV6-ABL1 fusion
Marketa Zaliova et al.
HAEMATOLOGICA (2016)
Morphologically Occult Systemic Mastocytosis in Bone Marrow Clinicopathologic Features and an Algorithmic Approach to Diagnosis
Kaaren K. Reichard et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2015)
Hematolymphoid Neoplasms Associated With Rearrangements of PDGFRA, PDGFRB, and FGFR1
Francisco Vega et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2015)
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene
Elisa Rumi et al.
ANNALS OF HEMATOLOGY (2015)
Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression
Catherine A. Cargo et al.
BLOOD (2015)
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma et al.
BLOOD (2015)
Spectrum of Eosinophilic End-Organ Manifestations
Praveen Akuthota et al.
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2015)
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event
M. Jawhar et al.
LEUKEMIA (2015)
Chronic mast cell leukemia: A novel leukemia-variant with distinct morphological and clinical features
Peter Valent et al.
LEUKEMIA RESEARCH (2015)
Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes
Juliana Schwaab et al.
ANNALS OF HEMATOLOGY (2015)
The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease
G. Hoermann et al.
ALLERGY (2014)
Successful allogeneic stem cell transplantation with long-term remission of ETV6/FLT3-positive myeloid/lymphoid neoplasm with eosinophilia
Kazuhisa Chonabayashi et al.
ANNALS OF HEMATOLOGY (2014)
Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal
P. Valent et al.
ANNALS OF ONCOLOGY (2014)
Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?
Barbara J. Bain et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Epidemiology of systemic mastocytosis in Denmark
Sarah S. Cohen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA
Irina Sadovnik et al.
EXPERIMENTAL HEMATOLOGY (2014)
Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM
Ivan Alvarez-Twose et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Idiopathic, asymptomatic, and durable blood hypereosinophilia-still many unknowns
Grzegorz Helbig et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant
L. Falchi et al.
LEUKEMIA (2014)
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
K. G. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases
Gandhi Damaj et al.
PLOS ONE (2014)
ETV6/FLT3 fusion in a mixed-phenotype acute leukemia arising in lymph nodes in a patient with myeloproliferative neoplasm with eosinophilia
Niloufar Hosseini et al.
JOURNAL OF HEMATOPATHOLOGY (2014)
Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: Clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components
Sa A. Wang et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Comprehensive mutational profiling in advanced systemic mastocytosis
Juliana Schwaab et al.
BLOOD (2013)
CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis
Jose M. Morgado et al.
HISTOPATHOLOGY (2013)
Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated With a PCM1-JAK2 Fusion Gene
Elisa Rumi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase
G. Metzgeroth et al.
LEUKEMIA (2013)
Mortality in hypereosinophilic syndrome: 19 years of experience at Mayo Clinic with a review of the literature
Jenna C. Podjasek et al.
LEUKEMIA RESEARCH (2013)
Venom Immunotherapy in Patients with Clonal Mast Cell Disorders: Efficacy, Safety, and Practical Considerations
Patrizia Bonadonna et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2013)
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes
Peter Valent et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3
Christoph Walz et al.
BLOOD (2011)
Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia
Thomas Ernst et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
ABL1 fusion genes in hematological malignancies: a review
Etienne De Braekeleer et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
ETV6-ABL1-positive chronic myeloid leukemia: clinical and molecular response to tyrosine kinase inhibition
Fabiana Perna et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Improved Detection of the KIT D816V Mutation in Patients with Systemic Mastocytosis Using a Quantitative and Highly Sensitive Real-Time qPCR Assay
Thomas Kristensen et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2011)
Molecular characterization of paediatric idiopathic hypereosinophilia
Maria Cristina Rapanotti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature
Animesh Pardanani et al.
CURRENT OPINION IN HEMATOLOGY (2010)
Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms
Ivan Alvarez-Twose et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)
Karl Sotlar et al.
JOURNAL OF PATHOLOGY (2010)
Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine
Ken H. Lim et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
Ken-Hong Lim et al.
BLOOD (2009)
Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies
Animesh Pardanani et al.
BLOOD (2009)
Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapy
Princess U. Ogbogu et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients
Luis Escribano et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
t(8;13)-positive bilineal lymphomas - Report of 6 cases
Francisco Vega et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia
Jennifer L. Poitras et al.
GENES CHROMOSOMES & CANCER (2008)
Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3
A. Tzankov et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms
Vesna Naifeld et al.
EXPERIMENTAL HEMATOLOGY (2007)
A constitutively active SPTBNI-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy
Francis H. Grand et al.
EXPERIMENTAL HEMATOLOGY (2007)
KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders:: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients
Andres C. Garcia-Montero et al.
BLOOD (2006)
FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13) (p13;q12) translocation
Ha Vu et al.
LEUKEMIA (2006)
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2
A Reiter et al.
CANCER RESEARCH (2005)
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib
C Akin et al.
BLOOD (2004)
FIP1L1-PDGFRA fusion:: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
A Pardanani et al.
BLOOD (2004)
A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase
RP Million et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Imatinib for systemic mast-cell disease
A Pardanani et al.
LANCET (2003)
The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins
A Demiroglu et al.
BLOOD (2001)
Share Paper
